The US Congress approved several key cannabis provisions in the 2020 annual appropriations bill, which includes funding federal research into cannabinoids and hemp, as well as crafting new regulations around CBD.<\/p>\n
So, what\u2019s on the list<\/u><\/a> for cannabis, exactly? Perhaps the most consequential provision, for now, is the $2 million going to the FDA to help the agency finally draft some solid CBD regulations. CBD, or cannabidiol<\/u><\/a>, is a non-intoxicating component of cannabis with some accepted medical use. Currently, estimates place the CBD market around $2 billion<\/u><\/a>. <\/p>\n The FDA has not regulated the fledgling CBD market beyond sending cease-and-desist letters<\/u><\/a> to companies that have made health claims on their CBD products. So far, the FDA has only approved of one CBD product for medical use \u2014 Epidiolex<\/u><\/a>, a CBD drug made from cannabis, used to treat rare seizure disorders.<\/p>\n CBD regulations could include standard dose amounts, required contaminant testing, or warning labels. <\/p>\n